[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559504":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":25,"interventions":38,"overallOfficials":48,"centralContacts":55,"locations":65,"responsibleParty":100,"collaborators":13,"id":102,"slug":13,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":13,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":13,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":13,"overallStatus":67,"whyStopped":13,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Cleveland Dental Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Electromyograph","Signs of loss of sensation in the involved side of the jaw will be recorded using a tool called Electromyograph machine to evaluate and record Nerve conduction velocity, the scale is as follow Normal (grade 0) to extremely damage of (grade 6) while a patient rate pain intensity on a Visual Analogue Scale (VAS).","3 months",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"QUADRUPLE",[21,22,23,24],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[26,32],{"label":27,"type":28,"description":29,"interventionNames":30},"Articaine","EXPERIMENTAL","Inferior Alveolar Nerve block using Articaine 4% with 1:200,000 epinephrine local anesthetic",[31],"Drug: 4% Articaine with 1:200,000 epinephrine",{"label":33,"type":34,"description":35,"interventionNames":36},"Lidocaine","ACTIVE_COMPARATOR","Inferior Alveolar Nerve block using 2% lidocaine with 1:100,000 epinephrine local anesthetic",[37],"Drug: 2% lidocaine with 1:100,000 epinephrine",[39,44],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":13},"DRUG","4% Articaine with 1:200,000 epinephrine","Inferior Alveolar Nerve Block with 4% articaine",[27],{"type":40,"name":45,"description":46,"armGroupLabels":47,"otherNames":13},"2% lidocaine with 1:100,000 epinephrine","Inferior Alveolar Nerve Block with 2% lidocaine",[33],[49,52],{"name":50,"affiliation":5,"role":51},"Ahmed A Hashem, PhD","STUDY_DIRECTOR",{"name":53,"affiliation":5,"role":54},"Waleed Elmallah, PhD","PRINCIPAL_INVESTIGATOR",[56,61],{"name":57,"role":58,"phone":59,"phoneExt":13,"email":60},"Pablo R Velazquez, Resident","CONTACT","7546108595","p.velazquez@cdiohio.org",{"name":62,"role":58,"phone":63,"phoneExt":13,"email":64},"Nelson A Rendon, Resident","9548605748","n.rendon@cdiohio.org",[66,91],{"facility":5,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"RECRUITING","Akron","Ohio","44703","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-81.51901,41.08144,{"lat":77,"lon":76},[80,83,86,89],{"name":53,"role":58,"phone":81,"phoneExt":13,"email":82},"216-333-6695","w.elmallah@cdiohio.org",{"name":50,"role":58,"phone":84,"phoneExt":13,"email":85},"4405021591","a.hashem@cdiohio.org",{"name":87,"role":88,"phone":13,"phoneExt":13,"email":13},"Pablo Velazquez, resident","SUB_INVESTIGATOR",{"name":90,"role":88,"phone":13,"phoneExt":13,"email":13},"Nelson Rendon, resident",{"facility":5,"status":92,"city":93,"state":69,"zip":94,"country":71,"countryCode":72,"cosmosGeoPoint":95,"geoPoint":99,"contacts":13},"ACTIVE_NOT_RECRUITING","Ashtabula","44004",{"type":74,"coordinates":96},[97,98],-80.78981,41.86505,{"lat":98,"lon":97},{"type":101,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100559504",false,"NCT06564987","Risk of Nerve Damage After Administration of Local Anesthesia","Risk of Nerve Damage After Administration of an Inferior Alveolar Nerve Block Using 4% Articaine Versus 2% Lidocaine","Inclusion Criteria:\n\n* Patients with age between 18-55 years old\n* Patients need IANB\n* healthy patient\n\nExclusion Criteria:\n\n* medical conditions\n* allergies\n* medications\n* pregnancy and breastfeeding\n* inability to provide informed consent\n* specific dental or medical history.",true,"ALL","18 Years","55 Years",{"count":113,"type":114},80,"ESTIMATED","INTERVENTIONAL",[117],"PHASE1","This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine 2%. The type of LA will be concealed to the operator, investigators and assessors. The patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.",[120],"Inferior Alveolar Nerve Injuries","2024-08-23",{"date":123,"type":124},"2024-08-26","ACTUAL",{"date":126,"type":124},"2024-01-01",{"date":128,"type":114},"2025-03-31",{"name":5,"class":6},2]